New York, New York--(Newsfile Corp. - August 27, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate ...
At FDA's request, Type D Meeting expected in March 2026 to review Comparative Oncology biomarker data from patients treated in OST-HER2 Phase 2b human clinical trial and OST-HER2 trial in spontaneous ...
Beat Saber will receive OST 8 next month, marking the first OST release in over a year. As a reminder, these Beat Saber tracks won't be available on either PlayStation VR or PlayStation VR2. Meta ...
Interim analysis data show improvements in overall survival with OST-HER2 in this osteosarcoma population compared with historical controls. Treatment with the investigational HER2-directed ...
ROCKVILLE, Md.--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage oncology-focused immunotherapy company developing cancer vaccines and antibody drug conjugate (ADC) therapeutic ...
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced ...
Former Beat Games CEO and current Head of Music revealed late last year during a video livestream (more details here) that the “theme” for OST 4 will be “guitars and synthetic guitars” with “metal-ish ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results